Linked Life Data

16787462

Source:http://linkedlifedata.com/resource/pubmed/id/16787462

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-6-21
pubmed:abstractText
Solaraze gel (Shire Deutschland GmbH & Co. KG, Cologne, Germany) containing 3% diclofenac has been licensed in 2001 as a topical treatment for actinic keratoses. It is commonly used in dermatological practice. Undesirable effects are believed to be rare but include pruritus, paresthesia and application-site reactions (dry skin, rash, erythema, contact dermatitis and vesicobullous eruptions). Recently, a few cases of contact dermatitis due to three different allergens including diclofenac have been reported (1,2).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0105-1873
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
348-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Photoallergic contact dermatitis from topical diclofenac in Solaraze gel.
pubmed:affiliation
Klinik für Hautkrankheiten und Allergologie, HUMAINE Vogtland-Klinikum Plauen, Plauen, Germany. lutz.kowalzick@web.de
pubmed:publicationType
Journal Article, Case Reports